Media Coverage

“Proteomics International (PIQ) has been awarded over $400,000 in funding to manufacture its predict...

The Company is pleased to announce the publication of a Medtech Innovation Briefing (MIB) on the Pro...

The prevalence of diabetes is increasing worldwide, particularly in Asian countries, which contribut...

The Company is pleased to provide an opportunity for shareholders and investors to view a virtual pr...

The Company is pleased to announce that its cash reserves have been further strengthened by the rece...

“The company is commercialising its Promarker D predictive test for diabetic kidney disease. The gov...

“The result was welcomed by the Perth-based medical technology company as an “exciting milestone” in...

The Company is pleased to announce its prototype diagnostic test for oesophageal adenocarcinoma has ...

Spin-off business OxiDx founded to unlock value from ‘2-tag’ measure for oxidative stress.

“The WA-based medical technology company and the university have set up an incorporated joint ventur...

“Proteomics International Laboratories Ltd managing director Dr Richard Lipscombe introduces Proacti...

“Women with endometriosis may soon be able to take a simple blood test to determine if they have the...

Proteomics International Laboratories Ltd, a pioneer in predictive diagnostics, is pleased to advise...

We are pleased to announce the signing of a binding and exclusive letter of intent (LOI) with Sonic ...

We are pleased to announce that a study demonstrating the clinical utility of the PromarkerD test in...

“A survey of 400 physicians and endocrinologists in a clinical utility study found 78 per cent were ...

“However, [endometriosis] goes undiagnosed for an average of 7.5 years. The condition currently is b...

We are pleased to announce that an early version of the Company’s potential world-first blood test f...

Proteomics International Laboratories Ltd is pleased to announce that its European patent protection...

Preliminary results show several plasma proteins are statistically significant biomarkers for endome...

“We envisaged that blood test-based screening will allow better use of health resources by identifyi...

The Company has secured an exclusive worldwide licence to commercialise biomarkers that can test for...

“Under the contract, QIMR’s intellectual property in the biomarkers will become licensed exclusively...

The Company has successfully produced a pilot batch of PromarkerD test components with specialist im...

“Proteomics Managing Director Richard Lipscombe said the pilot production run was a big step in demo...

“The pilot batch was produced primarily for quality control and regulatory testing. However, some co...

The Company is pleased to announce the results of a study demonstrating the potential ability of the...

“The test already has the ability to predict the onset of the condition up to four years in advance,...

Proteomics International Laboratories Ltd is pleased to announce it has filed a submission to the Au...

Proteomics International managing director Dr Richard Lipscombe said the funding would supplement th...

Proteomics International Managing Director Dr Richard Lipscombe said, “Our new Clinical Advisory Boa...

Proteomics International Managing Director Dr Richard Lipscombe said, “Our new Clinical Advisory Boa...

Medical technology company Proteomics International Laboratories has reinforced its presence in Indi...

Granted India patent adds to an already strong and existing portfolio of patents and joins those alr...

The application lays the groundwork for the test to be added to the Medicare Benefit Schedule (MBS)....

“If MSAC recommendation is secured, it will be a key milestone in commercialising PromarkerD in Aust...

Proof-of-concept study identifies multiple protein biomarkers with potential to test for obstructive...

Proteomics International Managing Director Dr Richard Lipscombe said the research studied multiple p...

“Your Friday crash course: Diagnostic biomarkers are in essence, used to determine whether or not a ...

Company Newsletter January 2022